CNTA Stock Analysis: Buy, Sell, or Hold?
CNTA - Centessa Pharmaceuticals plc American Depositary Shares
$39.61
0.01 (0.04%)
▲
5d:
+0.04%
30d:
-0.14%
90d:
+58.8%
BUY
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 18, 2026
0d
Get Alerted When CNTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CNTA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CNTA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CNTA is currently trading at $39.60, which is considered slightly high relative to its 30-day fair value range of $39.48 to $39.64.
Technical Outlook: Technically, CNTA is in a strong uptrend. The price is currently testing key support at $39.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $44.57 (+12.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CNTA is in a strong uptrend. The price is currently testing key support at $39.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $44.57 (+12.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$39.48 -
$39.64
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
64.2%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($44.57)
Trading Range Analysis
30-Day Trading Range
$39.48 -
$39.64
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$39.52
Resistance Level
$39.84
Current Trend
Strong Uptrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.86
Wall Street Target
$44.57
(+12.6%)
Share & Embed Analysis
Last updated: May 18, 2026 1:01 PM ET
Data refreshes hourly during market hours. Next update: 2:01 PM
Data refreshes hourly during market hours. Next update: 2:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Karen M Anderson
SELL
41076 shares
2026-03-26
Karen M Anderson
SELL
10043 shares
2026-03-17
Karen M Anderson
SELL
64768 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 50 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$293 | 60 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 42 HOLD |
